PR Newswire10.31.16
Onkos Surgical, a surgical oncology company founded by Patrick Treacy, Anthony Koblish, and 1315 Capital has announced today it has received clearance from the U.S. Food and Drug Administration to market the ELEOS Limb Salvage System to treat patients with significant bone loss due to cancer, trauma, or previous surgical procedures.
"Surgical Oncology has been an underserved market for some time," said Patrick Treacy, Founder and CEO. "These surgeons and patients deserve more. With the introduction of the ELEOS Limb Salvage System, we will continue to build on our promise of delivering meaningful innovation in the orthopedic oncology market. Our company is focused and dedicated to bringing solutions to this group of surgeons and patients that will address the significant unmet need that exists. Today is a very important milestone for our company and we look forward to executing on our robust pipeline of innovation."
Dr. Steven Gitelis, Professor and Vice Chairman, Department of Orthopedic Surgery, at Rush University Medical Center and an Onkos Surgical Surgeon Advisory Board member said, "Tumor surgery is often personalized as each patient presents differently. When replacing bone with an implant, ELEOS provides the flexibility and modularity a surgeon needs for these complex cases. The ELEOS system is a long term reconstructive option for oncology patients. Our patient population is unique and we need a company like Onkos to provide innovation where we have our most challenging need."
"We will continue to leverage ELEOS and our 3D printing capabilities to drive our innovation initiatives," said Treacy. "ELEOS will be a foundational system for the company and we are planning for a full launch in the first quarter of 2017."
"Surgical Oncology has been an underserved market for some time," said Patrick Treacy, Founder and CEO. "These surgeons and patients deserve more. With the introduction of the ELEOS Limb Salvage System, we will continue to build on our promise of delivering meaningful innovation in the orthopedic oncology market. Our company is focused and dedicated to bringing solutions to this group of surgeons and patients that will address the significant unmet need that exists. Today is a very important milestone for our company and we look forward to executing on our robust pipeline of innovation."
Dr. Steven Gitelis, Professor and Vice Chairman, Department of Orthopedic Surgery, at Rush University Medical Center and an Onkos Surgical Surgeon Advisory Board member said, "Tumor surgery is often personalized as each patient presents differently. When replacing bone with an implant, ELEOS provides the flexibility and modularity a surgeon needs for these complex cases. The ELEOS system is a long term reconstructive option for oncology patients. Our patient population is unique and we need a company like Onkos to provide innovation where we have our most challenging need."
"We will continue to leverage ELEOS and our 3D printing capabilities to drive our innovation initiatives," said Treacy. "ELEOS will be a foundational system for the company and we are planning for a full launch in the first quarter of 2017."